Relationship between matrix metalloproteinase 2 and lung cancer progression

Matrix metalloproteinases (MMPs) play an important role in several steps of cancer development. MMP2 and MMP9 have previously been implicated in lymphatic and vascular invasion of lung cancer; however, the expression and prognostic significance of MMP2 and MMP9 is not fully clarified. This study was...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular diagnosis & therapy 2007-01, Vol.11 (3), p.183-192
Hauptverfasser: Guo, Chun-Bao, Wang, Shan, Deng, Chun, Zhang, Dian-Liang, Wang, Fu-Ling, Jin, Xian-Qing
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 192
container_issue 3
container_start_page 183
container_title Molecular diagnosis & therapy
container_volume 11
creator Guo, Chun-Bao
Wang, Shan
Deng, Chun
Zhang, Dian-Liang
Wang, Fu-Ling
Jin, Xian-Qing
description Matrix metalloproteinases (MMPs) play an important role in several steps of cancer development. MMP2 and MMP9 have previously been implicated in lymphatic and vascular invasion of lung cancer; however, the expression and prognostic significance of MMP2 and MMP9 is not fully clarified. This study was designed to investigate the significance of MMP2 and MMP9 in lung cancer tissue or serum, and their correlation with lung cancer prognosis. Immunohistochemical analysis was performed to determine MMP2 and MMP9 staining in human nonsmall cell lung cancer (NSCLC). Serum MMP2 and MMP9 protein levels in patients after surgery were measured using the ELISA method. The correlation between MMP2 and MMP9 serum levels and clinicopathological features of NSCLC were analyzed by survival analysis. We also performed reverse transcriptase (RT)-PCR assays to detect messenger RNA (mRNA) expression to further confirm the activity of MMP2 and MMP9 in human lung cancer. Increased MMP2 immunostaining and MMP2 serum level correlated with advanced tumor stage and the presence of distant metastasis (Pearson's chi(2) test and ANOVA, p < 0.05). However, for MMP9, only serum level showed a correlation with advanced tumor stage. No significant correlation was observed between MMP2 or MMP9 immunostaining expression and tumor histologic features (Pearson's chi(2) test, p = 0.061 and p = 0.087, respectively). A high densitometry value of MMP2 and MMP9 PCR products (i.e. mRNA expression level) was related to poor differentiation grade, distant metastasis, and small cell carcinoma histologic type (ANOVA, p < 0.05). Our results suggest that MMP2 is a more sensitive predictor than MMP9 of lung cancer progression, metastasis, and survival. Serum MMP2 levels may be a valuable prognosis variable and could help to stratify lung cancer patients into low- and high-risk groups.
doi_str_mv 10.1007/bf03256240
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_70612387</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A200979742</galeid><sourcerecordid>A200979742</sourcerecordid><originalsourceid>FETCH-LOGICAL-c449t-f35ccc9e2ba364059a5239258406411982c96b7a32c1d1c12e97e187142138ff3</originalsourceid><addsrcrecordid>eNqFkUtLw0AQxxdRrK-LH0ACggchdfaRbPZYi1WxIIiew2Y7qSvJpu6mqN_era2IIMgcZpj5zYP5E3JMYUgB5EVVA2dZzgRskT1KpUoZAGx_xTKlkLMB2Q_hBUBkuWK7ZEBlJkEK2CN3D9jo3nYuPNtFUmH_huiSVvfevict9rppuoXverROB0xYot0saZZunhjtDPokFuceQ4gjDslOrZuARxt_QJ4mV4_jm3R6f307Hk1TI4Tq05pnxhiFrNI8F5ApnTGuWFYIyAWlqmBG5ZXUnBk6o4YyVBJpIalglBd1zQ_I2Xpu3P26xNCXrQ0Gm0Y77JahlJBTxgv5Lxh3xbcVPIKna3CuGyytq7vea7OCy1H8pZJKChap4R9UtBm21nQOaxvzvxrO1w3GdyF4rMuFt632HyWFciVdeTn5li7CJ5tjl1WLsx90oxX_BFzkkLk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19856283</pqid></control><display><type>article</type><title>Relationship between matrix metalloproteinase 2 and lung cancer progression</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Guo, Chun-Bao ; Wang, Shan ; Deng, Chun ; Zhang, Dian-Liang ; Wang, Fu-Ling ; Jin, Xian-Qing</creator><creatorcontrib>Guo, Chun-Bao ; Wang, Shan ; Deng, Chun ; Zhang, Dian-Liang ; Wang, Fu-Ling ; Jin, Xian-Qing</creatorcontrib><description>Matrix metalloproteinases (MMPs) play an important role in several steps of cancer development. MMP2 and MMP9 have previously been implicated in lymphatic and vascular invasion of lung cancer; however, the expression and prognostic significance of MMP2 and MMP9 is not fully clarified. This study was designed to investigate the significance of MMP2 and MMP9 in lung cancer tissue or serum, and their correlation with lung cancer prognosis. Immunohistochemical analysis was performed to determine MMP2 and MMP9 staining in human nonsmall cell lung cancer (NSCLC). Serum MMP2 and MMP9 protein levels in patients after surgery were measured using the ELISA method. The correlation between MMP2 and MMP9 serum levels and clinicopathological features of NSCLC were analyzed by survival analysis. We also performed reverse transcriptase (RT)-PCR assays to detect messenger RNA (mRNA) expression to further confirm the activity of MMP2 and MMP9 in human lung cancer. Increased MMP2 immunostaining and MMP2 serum level correlated with advanced tumor stage and the presence of distant metastasis (Pearson's chi(2) test and ANOVA, p &lt; 0.05). However, for MMP9, only serum level showed a correlation with advanced tumor stage. No significant correlation was observed between MMP2 or MMP9 immunostaining expression and tumor histologic features (Pearson's chi(2) test, p = 0.061 and p = 0.087, respectively). A high densitometry value of MMP2 and MMP9 PCR products (i.e. mRNA expression level) was related to poor differentiation grade, distant metastasis, and small cell carcinoma histologic type (ANOVA, p &lt; 0.05). Our results suggest that MMP2 is a more sensitive predictor than MMP9 of lung cancer progression, metastasis, and survival. Serum MMP2 levels may be a valuable prognosis variable and could help to stratify lung cancer patients into low- and high-risk groups.</description><identifier>ISSN: 1177-1062</identifier><identifier>EISSN: 1179-2000</identifier><identifier>DOI: 10.1007/bf03256240</identifier><identifier>PMID: 17570740</identifier><language>eng</language><publisher>New Zealand: Wolters Kluwer Health, Inc</publisher><subject>Adenocarcinoma - enzymology ; Adenocarcinoma - pathology ; Adult ; Aged ; Carcinoma, Non-Small-Cell Lung - enzymology ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Small Cell - enzymology ; Carcinoma, Small Cell - pathology ; Carcinoma, Squamous Cell - enzymology ; Carcinoma, Squamous Cell - pathology ; Disease Progression ; Female ; Humans ; Lung Neoplasms - enzymology ; Lung Neoplasms - pathology ; Male ; Matrix Metalloproteinase 2 - metabolism ; Matrix Metalloproteinase 9 - metabolism ; Middle Aged ; Neoplasm Metastasis ; RNA, Messenger - metabolism ; Survival Analysis</subject><ispartof>Molecular diagnosis &amp; therapy, 2007-01, Vol.11 (3), p.183-192</ispartof><rights>COPYRIGHT 2007 Wolters Kluwer Health, Inc.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c449t-f35ccc9e2ba364059a5239258406411982c96b7a32c1d1c12e97e187142138ff3</citedby><cites>FETCH-LOGICAL-c449t-f35ccc9e2ba364059a5239258406411982c96b7a32c1d1c12e97e187142138ff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17570740$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guo, Chun-Bao</creatorcontrib><creatorcontrib>Wang, Shan</creatorcontrib><creatorcontrib>Deng, Chun</creatorcontrib><creatorcontrib>Zhang, Dian-Liang</creatorcontrib><creatorcontrib>Wang, Fu-Ling</creatorcontrib><creatorcontrib>Jin, Xian-Qing</creatorcontrib><title>Relationship between matrix metalloproteinase 2 and lung cancer progression</title><title>Molecular diagnosis &amp; therapy</title><addtitle>Mol Diagn Ther</addtitle><description>Matrix metalloproteinases (MMPs) play an important role in several steps of cancer development. MMP2 and MMP9 have previously been implicated in lymphatic and vascular invasion of lung cancer; however, the expression and prognostic significance of MMP2 and MMP9 is not fully clarified. This study was designed to investigate the significance of MMP2 and MMP9 in lung cancer tissue or serum, and their correlation with lung cancer prognosis. Immunohistochemical analysis was performed to determine MMP2 and MMP9 staining in human nonsmall cell lung cancer (NSCLC). Serum MMP2 and MMP9 protein levels in patients after surgery were measured using the ELISA method. The correlation between MMP2 and MMP9 serum levels and clinicopathological features of NSCLC were analyzed by survival analysis. We also performed reverse transcriptase (RT)-PCR assays to detect messenger RNA (mRNA) expression to further confirm the activity of MMP2 and MMP9 in human lung cancer. Increased MMP2 immunostaining and MMP2 serum level correlated with advanced tumor stage and the presence of distant metastasis (Pearson's chi(2) test and ANOVA, p &lt; 0.05). However, for MMP9, only serum level showed a correlation with advanced tumor stage. No significant correlation was observed between MMP2 or MMP9 immunostaining expression and tumor histologic features (Pearson's chi(2) test, p = 0.061 and p = 0.087, respectively). A high densitometry value of MMP2 and MMP9 PCR products (i.e. mRNA expression level) was related to poor differentiation grade, distant metastasis, and small cell carcinoma histologic type (ANOVA, p &lt; 0.05). Our results suggest that MMP2 is a more sensitive predictor than MMP9 of lung cancer progression, metastasis, and survival. Serum MMP2 levels may be a valuable prognosis variable and could help to stratify lung cancer patients into low- and high-risk groups.</description><subject>Adenocarcinoma - enzymology</subject><subject>Adenocarcinoma - pathology</subject><subject>Adult</subject><subject>Aged</subject><subject>Carcinoma, Non-Small-Cell Lung - enzymology</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Small Cell - enzymology</subject><subject>Carcinoma, Small Cell - pathology</subject><subject>Carcinoma, Squamous Cell - enzymology</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - enzymology</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Matrix Metalloproteinase 2 - metabolism</subject><subject>Matrix Metalloproteinase 9 - metabolism</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>RNA, Messenger - metabolism</subject><subject>Survival Analysis</subject><issn>1177-1062</issn><issn>1179-2000</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtLw0AQxxdRrK-LH0ACggchdfaRbPZYi1WxIIiew2Y7qSvJpu6mqN_era2IIMgcZpj5zYP5E3JMYUgB5EVVA2dZzgRskT1KpUoZAGx_xTKlkLMB2Q_hBUBkuWK7ZEBlJkEK2CN3D9jo3nYuPNtFUmH_huiSVvfevict9rppuoXverROB0xYot0saZZunhjtDPokFuceQ4gjDslOrZuARxt_QJ4mV4_jm3R6f307Hk1TI4Tq05pnxhiFrNI8F5ApnTGuWFYIyAWlqmBG5ZXUnBk6o4YyVBJpIalglBd1zQ_I2Xpu3P26xNCXrQ0Gm0Y77JahlJBTxgv5Lxh3xbcVPIKna3CuGyytq7vea7OCy1H8pZJKChap4R9UtBm21nQOaxvzvxrO1w3GdyF4rMuFt632HyWFciVdeTn5li7CJ5tjl1WLsx90oxX_BFzkkLk</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>Guo, Chun-Bao</creator><creator>Wang, Shan</creator><creator>Deng, Chun</creator><creator>Zhang, Dian-Liang</creator><creator>Wang, Fu-Ling</creator><creator>Jin, Xian-Qing</creator><general>Wolters Kluwer Health, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>7X8</scope></search><sort><creationdate>20070101</creationdate><title>Relationship between matrix metalloproteinase 2 and lung cancer progression</title><author>Guo, Chun-Bao ; Wang, Shan ; Deng, Chun ; Zhang, Dian-Liang ; Wang, Fu-Ling ; Jin, Xian-Qing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c449t-f35ccc9e2ba364059a5239258406411982c96b7a32c1d1c12e97e187142138ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adenocarcinoma - enzymology</topic><topic>Adenocarcinoma - pathology</topic><topic>Adult</topic><topic>Aged</topic><topic>Carcinoma, Non-Small-Cell Lung - enzymology</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Small Cell - enzymology</topic><topic>Carcinoma, Small Cell - pathology</topic><topic>Carcinoma, Squamous Cell - enzymology</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - enzymology</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Matrix Metalloproteinase 2 - metabolism</topic><topic>Matrix Metalloproteinase 9 - metabolism</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>RNA, Messenger - metabolism</topic><topic>Survival Analysis</topic><toplevel>online_resources</toplevel><creatorcontrib>Guo, Chun-Bao</creatorcontrib><creatorcontrib>Wang, Shan</creatorcontrib><creatorcontrib>Deng, Chun</creatorcontrib><creatorcontrib>Zhang, Dian-Liang</creatorcontrib><creatorcontrib>Wang, Fu-Ling</creatorcontrib><creatorcontrib>Jin, Xian-Qing</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular diagnosis &amp; therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guo, Chun-Bao</au><au>Wang, Shan</au><au>Deng, Chun</au><au>Zhang, Dian-Liang</au><au>Wang, Fu-Ling</au><au>Jin, Xian-Qing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relationship between matrix metalloproteinase 2 and lung cancer progression</atitle><jtitle>Molecular diagnosis &amp; therapy</jtitle><addtitle>Mol Diagn Ther</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>11</volume><issue>3</issue><spage>183</spage><epage>192</epage><pages>183-192</pages><issn>1177-1062</issn><eissn>1179-2000</eissn><abstract>Matrix metalloproteinases (MMPs) play an important role in several steps of cancer development. MMP2 and MMP9 have previously been implicated in lymphatic and vascular invasion of lung cancer; however, the expression and prognostic significance of MMP2 and MMP9 is not fully clarified. This study was designed to investigate the significance of MMP2 and MMP9 in lung cancer tissue or serum, and their correlation with lung cancer prognosis. Immunohistochemical analysis was performed to determine MMP2 and MMP9 staining in human nonsmall cell lung cancer (NSCLC). Serum MMP2 and MMP9 protein levels in patients after surgery were measured using the ELISA method. The correlation between MMP2 and MMP9 serum levels and clinicopathological features of NSCLC were analyzed by survival analysis. We also performed reverse transcriptase (RT)-PCR assays to detect messenger RNA (mRNA) expression to further confirm the activity of MMP2 and MMP9 in human lung cancer. Increased MMP2 immunostaining and MMP2 serum level correlated with advanced tumor stage and the presence of distant metastasis (Pearson's chi(2) test and ANOVA, p &lt; 0.05). However, for MMP9, only serum level showed a correlation with advanced tumor stage. No significant correlation was observed between MMP2 or MMP9 immunostaining expression and tumor histologic features (Pearson's chi(2) test, p = 0.061 and p = 0.087, respectively). A high densitometry value of MMP2 and MMP9 PCR products (i.e. mRNA expression level) was related to poor differentiation grade, distant metastasis, and small cell carcinoma histologic type (ANOVA, p &lt; 0.05). Our results suggest that MMP2 is a more sensitive predictor than MMP9 of lung cancer progression, metastasis, and survival. Serum MMP2 levels may be a valuable prognosis variable and could help to stratify lung cancer patients into low- and high-risk groups.</abstract><cop>New Zealand</cop><pub>Wolters Kluwer Health, Inc</pub><pmid>17570740</pmid><doi>10.1007/bf03256240</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1177-1062
ispartof Molecular diagnosis & therapy, 2007-01, Vol.11 (3), p.183-192
issn 1177-1062
1179-2000
language eng
recordid cdi_proquest_miscellaneous_70612387
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Adenocarcinoma - enzymology
Adenocarcinoma - pathology
Adult
Aged
Carcinoma, Non-Small-Cell Lung - enzymology
Carcinoma, Non-Small-Cell Lung - pathology
Carcinoma, Small Cell - enzymology
Carcinoma, Small Cell - pathology
Carcinoma, Squamous Cell - enzymology
Carcinoma, Squamous Cell - pathology
Disease Progression
Female
Humans
Lung Neoplasms - enzymology
Lung Neoplasms - pathology
Male
Matrix Metalloproteinase 2 - metabolism
Matrix Metalloproteinase 9 - metabolism
Middle Aged
Neoplasm Metastasis
RNA, Messenger - metabolism
Survival Analysis
title Relationship between matrix metalloproteinase 2 and lung cancer progression
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T16%3A11%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relationship%20between%20matrix%20metalloproteinase%202%20and%20lung%20cancer%20progression&rft.jtitle=Molecular%20diagnosis%20&%20therapy&rft.au=Guo,%20Chun-Bao&rft.date=2007-01-01&rft.volume=11&rft.issue=3&rft.spage=183&rft.epage=192&rft.pages=183-192&rft.issn=1177-1062&rft.eissn=1179-2000&rft_id=info:doi/10.1007/bf03256240&rft_dat=%3Cgale_proqu%3EA200979742%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19856283&rft_id=info:pmid/17570740&rft_galeid=A200979742&rfr_iscdi=true